Retatrutide Risk editors
Published · Updated
Every guide on this site carries the byline “Retatrutide Risk editors”. This page says who that is, what the desk reads, how it checks a figure before it goes on a page, and who pays for the site.
Who we are
The byline belongs to the editorial desk of Retatrutide Risk, not to a named person. The desk reads the primary literature on retatrutide and writes it up in plain language. Nobody on it is a licensed physician, no guide is medically reviewed, and nothing on this site is medical advice. We would rather say that plainly than borrow authority we do not have.
What we read
- Peer-reviewed papers with a DOI registered at CrossRef. For retatrutide these are the phase 1 and phase 2 papers in Cell Metabolism, The Lancet, the New England Journal of Medicine and Nature Medicine.
- Trial registrations on ClinicalTrials.gov, read through the official API, for design, doses, enrollment and completion dates.
- FDA prescribing information for approved drugs of the same class, such as tirzepatide, used only for class-level warnings and labelled that way.
- Dated Eli Lilly announcements for phase 3 topline results that no journal has published yet, labelled “company announcement, not peer-reviewed”.
Forum posts, social media, vendor pages and other blogs are never the source of a figure.
How we check
Before a DOI goes on a page, the desk resolves it through the CrossRef API and compares the returned title, journal and authors with the citation. Each NCT number is resolved against its ClinicalTrials.gov record. A reference that cannot be verified is dropped. Figures are copied from the source with their unit and time point, not rounded or recomputed. Where the trials did not measure something, the guide says so. Doses appear only as they were given in registered trials; the desk does not write dosing recommendations.
Who publishes us
This site is published by OX RESEARCH LTD (company number 17464288), the company behind OXpeptides. OXpeptides sells research-use retatrutide, and the “Our pick” card and the bar at the bottom of each page link to it. That is our conflict of interest, and you should read the guides knowing it. The link does not decide which studies are cited or how findings are described; the editorial policy explains how the two are kept apart. The site runs no advertising, no analytics and no cookies.
Guides signed by the desk
- Retatrutide side effects: every adverse event the trials have reported so far
Published · Updated - Retatrutide results: the weight loss numbers from every trial, by dose and by week
Published · Updated - GLP-3 side effects: what the retatrutide trials actually report, dose by dose
Published · Updated
Contact and corrections
Corrections, missing sources and questions go to hello@retatrutiderisk.com, and corrections are answered first. When a guide changes in substance, its update date changes with it. More on the site itself on the about page.
